U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06966674) titled 'No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track' on May 04.
Brief Summary: This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.
Study Start Date: May 12
Study Type: INTERVENTIONAL
Condition:
No-Reflow
STEMI
Intracoronary
Tirofiban
Intervention:
DRUG: Intracoronary tirofiban
Patients will receive intracoronary tirofiban (Aggrastat(R)) (25 mg/kg).
DRUG: Saline 0.9%
Patients will receive intracoronary saline 0.9% solution as a control group.
Recruitment Status: RECRUITING
Sponsor: Kafrel...